Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Proteostasis Therapeutics Reports Positive Results from European Cystic Fibrosis Research

Proteostasis Therapeutics' shares traded higher today after the company reported positive results in its European Cystic Fibrosis study of organoids grown from human stem cells. The firm believes the ongoing ex-vivo study supports initiation of a human clinical trial in mid-20...
Streetwise Reports | December 12, 2019 |

From Cystic Fibrosis to COVID-19: A Medical Solution Like No Other

(Image via Dymedso Inc.) Airway clearance therapy has been a cornerstone of treatments aimed at minimizing the devastating effects of airway obstruction, infection, and inflammation caused by a buildup of mucus in lung conditions … but finding a non-invasive solutio...
Stockhouse Editorial | December 8, 2020 |

Vivus Shares Climb 50% Higher on sNDA Approval for Exocrine Pancreatic Insufficiency Drug

Shares of Vivus traded higher after the FDA approved the company's supplemental New Drug Application for an improved formulation of PANCREAZE® (pancrelipase) for use in the treatment of exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. ...
Streetwise Reports | February 6, 2020 |

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'

The latest clinical trial results are dissected in a ROTH Capital Partners report. In a Sept. 26 research note, ROTH Capital Partners analyst Jerry Isaacson reported that AzurRx BioPharma Inc.'s (AZRX:NASDAQ) Phase 2 OPTION trial for lead candidate MS1819 in cystic ...
Streetwise Reports | October 1, 2019 |

Insmed Shares Trade 40% Higher on Phase 2 Top-Line Bronchiectasis Trial Data

Insmed Inc.'s shares traded higher today after the company reported positive top-line results from its Phase 2 WILLOW Study of INS1007 in patients with non-cystic fibrosis bronchiectasis. Global biopharmaceutical company Insmed Inc. (INSM:NASDAQ) , which is...
Streetwise Reports | February 4, 2020 |

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Earl...
Streetwise Reports | October 18, 2019 |

Electromed Earnings Spark a 25% Increase in Its Share Price

Shares of SmartVest maker Electromed traded 25% higher today after the firm reported Q1/20 earnings. The firm's shares set a 52-week high price after reporting a 14.1% increase in year-over-year quarterly revenue and a six-fold increase in net income per share. Develo...
Streetwise Reports | November 14, 2019 |

Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment

Shares of Savara opened nearly 140% higher today after the orphan lung disease company advised that the FDA has granted Breakthrough Therapy designation for the firm's Molgradex for treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). This morning orphan lun...
Streetwise Reports | January 2, 2020 |

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment

Shares of Intercept Pharmaceuticals rose today after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. This morning biopharmac...
Streetwise Reports | November 27, 2019 |

For Better or Worse? On the Verge of a New Era in Investing

(The Global 7500 aircraft. Image via Bombardier Inc.) If there is one thing that we have learned one year into the COVID-19 pandemic, we must often take things as they come, week by week, especially in a volatile market. It's no April Fool's prank. Each week, w...
Stockhouse Editorial | March 31, 2021 |
1 2 3